Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-cryopreserved Kx negative packed red cell concentrates to support hematopoietic stem cell transplantation in McLeod contiguous gene deletion syndrome.

Journal of human immunity·2026
Same author

Mechanical circulatory support for cardiogenic shock in takotsubo syndrome.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics.

Nature communications·2025
Same author

Utilizing artificial intelligence for the detection of hemarthrosis in hemophilia using point-of-care ultrasonography.

Research and practice in thrombosis and haemostasis·2024
Same author

The protean presentations of XK disease (McLeod syndrome): a case series with new observations and updates on previously reported families.

Frontiers in neuroscience·2024
Same author

Plasma and platelet lipidome changes in Fabry disease.

Clinica chimica acta; international journal of clinical chemistry·2024

Related Experiment Video

Updated: Mar 11, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K

Quarantine versus pathogen-reduced plasma-coagulation factor content and rotational thromboelastometry coagulation.

Oliver M Theusinger1, David Goslings2, Jan-Dirk Studt3

  • 1Institute of Anesthesiology, University and University Hospital Zurich, Zurich, Switzerland.

Transfusion
|November 29, 2016
PubMed
Summary

Pathogen reduction in fresh-frozen plasma (FFP) decreases coagulation factors and variability. This study found pathogen-reduced FFP (piFFP) had lower protein concentrations and altered hemostasis compared to quarantine-stored FFP (qFFP).

More Related Videos

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.7K
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.3K

Related Experiment Videos

Last Updated: Mar 11, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.7K
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.3K

Area of Science:

  • Transfusion Medicine
  • Hematology
  • Biochemistry

Background:

  • Fresh-frozen plasma (FFP) protein concentrations vary due to individual differences, blood groups, and processing methods.
  • Quarantine-stored plasma (qFFP) and pathogen-reduced FFP (piFFP) represent different FFP preparations with potentially distinct hemostatic profiles.

Purpose of the Study:

  • To compare the concentrations and variability of procoagulant and anticoagulant hemostasis proteins in qFFP and piFFP.
  • To evaluate the impact of pathogen reduction on endogenous thrombin potential (ETP) and overall hemostatic function.

Main Methods:

  • Analysis of 35 samples each of qFFP and piFFP from male Blood Group O donors.
  • Assessment of plasma protein content, including specific coagulation factors and inhibitors.
  • Measurement of thrombin generation potential (ETP) and clot formation using rotational thromboelastometry.

Main Results:

  • qFFP exhibited significantly higher concentrations of ADAMTS13, fibrinogen, FV, FVIII, FXIII, protein S, antithrombin, and α2 antiplasmin compared to piFFP.
  • piFFP demonstrated significantly lower variability in factor concentrations.
  • Pathogen reduction altered thrombin generation dynamics, showing longer lag times and lower peak thrombin generation at specific tissue factor concentrations in qFFP compared to piFFP.

Conclusions:

  • Pathogen reduction technology significantly reduces concentrations and variability of key procoagulant and anticoagulant factors in FFP.
  • While pathogen reduction impacts hemostasis, it did not lead to reduced ETP or supraphysiological thrombin generation.
  • Neither qFFP nor piFFP preparations are likely to be effective for treating fibrinogen deficiency.